



GENMAB TO ATTEND THREE UPCOMING INVESTOR CONFERENCES

Summary: Genmab's management will attend three upcoming investor conferences.

Copenhagen, Denmark; September 8, 2008 – Genmab A/S (OMX: GEN) announced today members of senior management will attend three investor conferences in the coming weeks.

September 17 – CFO David A. Eatwell will present at the Merrill Lynch Pharma, Biotech and Medtech Conference in London, UK at 10:35AM local time.

September 22 – CEO Lisa N. Drakeman, Ph.D. will present at the 2008 UBS Global Life Sciences Conference in New York, NY, USA at 8:00AM local time.

October 1 – CSO Prof. Jan van de Winkel, Ph.D. will attend the Lehman Brothers Healthcare Investor Event in London, UK.

Live and archived webcasts of the Merrill Lynch and UBS conference presentations will be available at Genmab's website at www.genmab.com.

About Genmab A/S

Genmab is a leading international biotechnology company focused on developing fully human antibody therapeutics for unmet medical needs. Using cutting-edge antibody technology, Genmab's world class discovery, development and manufacturing teams have created and developed an extensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders. As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section "Risk Management" in Genmab's Annual Report, which is available on www.genmab.com. Genmab

GENMAB TO ATTEND THREE UPCOMING INVESTOR CONFERENCES

does not undertake any obligation to update or revise forward looking statements in this press release nor to confirm such statements in relation to actual results, unless required by law.

Genmab[®]; the Y-shaped Genmab logo[®]; HuMax[®]; HuMax-CD4[®]; HuMax-CD20[®]; HuMax-EGFr[™]; HuMax-IL8[™]; HuMax-TAC[™]; HuMax-HepC[™]; HuMax-CD38[™]; HuMax-CD32b[™] and UniBody[®] are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations
T: +45 33 44 77 30; M: +45 25 27 47 13; E: hth@genmab.com

###